Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05163080
Title SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) (SURVIVE)
Acronym SURVIVE
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors MimiVax, LLC
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.